Overview

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-30

Target enrollment:

Participant gender:

Summary

This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG0015-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

CSPC Megalith Biopharmaceutical Co.,Ltd.

Treatments:

Capecitabine
Fluorouracil